Literature DB >> 34035075

Associations of Systolic Blood Pressure and Diastolic Blood Pressure With the Incidence of Coronary Artery Disease or Cerebrovascular Disease According to Glucose Status.

Mayuko Harada Yamada1,2, Kazuya Fujihara3, Satoru Kodama1, Takaaki Sato1, Taeko Osawa1, Yuta Yaguchi1, Masahiko Yamamoto1, Masaru Kitazawa1, Yasuhiro Matsubayashi1, Takaho Yamada1, Hiroyasu Seida4, Wataru Ogawa2, Hirohito Sone1.   

Abstract

OBJECTIVE: To determine associations of systolic blood pressure (SBP) and diastolic blood pressure (DBP) with new-onset coronary artery disease (CAD) or cerebrovascular disease (CVD) according to glucose status. RESEARCH DESIGN AND METHODS: Examined was a nationwide claims database from 2008 to 2016 on 593,196 individuals. A Cox proportional hazards model identified risks of CAD and CVD events among five levels of SBP and DBP.
RESULTS: During the study period 2,240 CAD and 3,207 CVD events occurred. Compared with SBP ≤119 mmHg, which was the lowest quintile of SBP, hazard ratios (95% CI) for CAD/CVD in the 4 higher quintiles (120-129, 130-139, 140-149, ≥150 mmHg) gradually increased from 2.10 (1.73-2.56)/1.46 (1.27-1.68) in quintile 2 to 3.21 (2.37-4.34)/4.76 (3.94-5.75) in quintile 5 for normoglycemia, from 1.39 (1.14-1.69)/1.70 (1.44-2.01) in quintile 2 to 2.52 (1.95-3.26)/4.12 (3.38-5.02) in quintile 5 for borderline glycemia, and from 1.50 (1.19-1.90)/1.72 (1.31-2.26) in quintile 2 to 2.52 (1.95-3.26)/3.54 (2.66-4.70) in quintile 5 for diabetes. A similar trend was observed for DBP across 4 quintiles (75-79, 80-84, 85-89, and ≥90 mmHg) compared with ≥74 mmHg, which was the lowest quintile.
CONCLUSIONS: Results indicated that cardiovascular risks gradually increased with increases in SBP and DBP regardless of the presence of and degree of a glucose abnormality. Further interventional trials are required to apply findings from this cohort study to clinical practice.
© 2021 by the American Diabetes Association.

Entities:  

Year:  2021        PMID: 34035075     DOI: 10.2337/dc20-2252

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  4 in total

1.  Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.

Authors:  Yasuhiro Matsubayashi; Kazuya Fujihara; Mayuko Yamada-Harada; Yurie Mitsuma; Takaaki Sato; Yuta Yaguchi; Taeko Osawa; Masahiko Yamamoto; Masaru Kitazawa; Takaho Yamada; Satoru Kodama; Hirohito Sone
Journal:  Cardiovasc Diabetol       Date:  2022-06-02       Impact factor: 8.949

Review 2.  There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.

Authors:  Michael E Makover; Michael D Shapiro; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2022-08-06

3.  Role of obesity and hypertension in the incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes.

Authors:  Lucia La Sala; Antonio E Pontiroli
Journal:  Cardiovasc Diabetol       Date:  2021-08-04       Impact factor: 9.951

4.  Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.

Authors:  Masato Yoneda; Takuma Yamamoto; Yasushi Honda; Kento Imajo; Yuji Ogawa; Takaomi Kessoku; Takashi Kobayashi; Asako Nogami; Takuma Higurashi; Shingo Kato; Kunihiro Hosono; Satoru Saito; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2021-10-03       Impact factor: 7.527

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.